LDLR and metabolic disease: All six founder pigsdisplayed biallelic inactivation of LDLR without finding off-targetincidents and serum values of cholesterol, LDL, and ApoB were enhancedremarkably, indicating that CRISPR/Cas9 approach can be utilized to simulatelipid metabolic disease and atherosclerotic models.